Selective Microvascular Tissue Transfection Using Minicircle DNA for Systemic Delivery of Human Coagulation Factor IX in a Rat Model Using a Therapeutic Flap

Background: Gene therapy is a promising treatment for protein deficiency disorders such as hemophilia B. However, low tissue selectivity and efficacy are limitations of systemic vector delivery. The authors hypothesized that selective transfection of rat superficial inferior epigastric artery flaps could provide systemic delivery of coagulation factor IX, preventing the need for systemic vector administration. Methods: Minicircle DNA containing green fluorescent protein, firefly luciferase, and human coagulation factor IX was created. Vector constructs were validated by transfecting adipose-derived stromal cells isolated from Wistar rat superficial inferior epigastric artery flaps and evaluating transgene expression by fluorescence microscopy, bioluminescence, and enzyme-linked immunosorbent assay. Minicircle DNA luciferase (10 and 30 μg) was injected into murine (wild-type, C57/BL/6) inguinal fat pads (n = 3) and followed by in vivo bioluminescence imaging for 60 days. Wistar rat superficial inferior epigastric artery flaps were transfected with minicircle DNA human coagulation factor IX (n = 9) with plasma and tissue transgene expression measured by enzyme-linked immunosorbent assay at 2 and 4 weeks. Results: Transfected adipose-derived stromal cells expressed green fluorescent protein for 30 days, luciferase for 43 days, and human coagulation factor IX (21.9 ± 1.2 ng/ml) for 28 days in vitro. In vivo murine studies demonstrated dose-dependence between minicircle DNA delivery and protein expression. Ex vivo rat superficial inferior epigastric artery flap transfection with minicircle DNA human coagulation factor IX showed systemic transgene expression at 2 (266.6 ± 23.4 ng/ml) and 4 weeks (290.1 ± 17.1 ng/ml) compared to control tissue (p < 0.0001). Conclusions: Rat superficial inferior epigastric artery flap transfection using minicircle DNA human coagulation factor IX resulted in systemic transgene detection, suggesting that selective flap or angiosome-based tissue transfection may be explored as a treatment for systemic protein deficiency disorders such as hemophilia B.

[1]  G. Fu,et al.  Photothermal-assisted surface-mediated gene delivery for enhancing transfection efficiency. , 2019, Biomaterials science.

[2]  G. Gurtner,et al.  Therapeutic Breast Reconstruction Using Gene Therapy–Delivered IFNγ Immunotherapy , 2019, Molecular Cancer Therapeutics.

[3]  Shan Zhu,et al.  Lentivirus-mediated CDglyTK gene-modified free flaps by intra-artery perfusion show targeted therapeutic efficacy in rat model of breast cancer , 2019, BMC Cancer.

[4]  G. Cesana,et al.  The socioeconomic burden of patients affected by hemophilia with inhibitors , 2018, European journal of haematology.

[5]  E. Seifried,et al.  Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. , 2018, Blood.

[6]  Hardev S. Pandha,et al.  Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues , 2018, Science Translational Medicine.

[7]  J. Rasko,et al.  Hemophilia B Gene Therapy with a High‐Specific‐Activity Factor IX Variant , 2017, The New England journal of medicine.

[8]  Skin regeneration with insights , 2017, Nature.

[9]  E. Rodríguez‐Merchán.  Treatment of musculo-skeletal pain in haemophilia. , 2017, Blood reviews.

[10]  Kevin J. Kauffman,et al.  Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system , 2016, Gene Therapy.

[11]  S. Moisyadi,et al.  Ultrasound-targeted hepatic delivery of factor IX in hemophiliac mice , 2016, Gene Therapy.

[12]  J. Church.  AAV-Expressed eCD4-Ig Provides Durable Protection From Multiple SHIV Challenges , 2015, Pediatrics.

[13]  R. Desrosiers,et al.  AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity , 2015, PLoS pathogens.

[14]  Baoshan Zhang,et al.  AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges , 2015, Nature.

[15]  Michael Recht,et al.  Long-term safety and efficacy of factor IX gene therapy in hemophilia B. , 2014, The New England journal of medicine.

[16]  R. Ljung,et al.  Definitions in hemophilia: communication from the SSC of the ISTH , 2014, Journal of thrombosis and haemostasis : JTH.

[17]  Yong Huang,et al.  Promoterless gene targeting without nucleases ameliorates haemophilia B in mice , 2014, Nature.

[18]  S. Ramakrishna,et al.  Enhanced gene disruption by programmable nucleases delivered by a minicircle vector , 2014, Gene Therapy.

[19]  S. Yamanaka,et al.  Delivery of Full-Length Factor VIII Using a piggyBac Transposon Vector to Correct a Mouse Model of Hemophilia A , 2014, PloS one.

[20]  P. Bosma,et al.  Adeno-Associated Viral Vector Serotype 5 Poorly Transduces Liver in Rat Models , 2013, PloS one.

[21]  Daniel T. Montoro,et al.  Enhancing In Vivo Survival of Adipose‐Derived Stromal Cells Through Bcl‐2 Overexpression Using a Minicircle Vector , 2013, Stem cells translational medicine.

[22]  D. Baltimore,et al.  Broad protection against influenza infection by vectored immunoprophylaxis in mice , 2013, Nature Biotechnology.

[23]  G. Wong,et al.  Intranasal Antibody Gene Transfer in Mice and Ferrets Elicits Broad Protection Against Pandemic Influenza , 2013, Science Translational Medicine.

[24]  P. Fagone,et al.  Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. , 2013, Blood.

[25]  F. Mavilio,et al.  Mechanisms of retroviral integration and mutagenesis. , 2013, Human gene therapy.

[26]  Kevin J Harrington,et al.  Targeted gene delivery by free-tissue transfer in oncoplastic reconstruction. , 2012, The Lancet. Oncology.

[27]  Pratima Chowdary,et al.  Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. , 2011, The New England journal of medicine.

[28]  Paul Liu,et al.  Enhancement of flap survival and changes in angiogenic gene expression after AAV2‐mediated VEGF gene transfer to rat ischemic flaps , 2011, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[29]  M. Kay,et al.  A Simple And Rapid Minicircle DNA Vector Manufacturing System , 2010, Nature Biotechnology.

[30]  Geoffrey C. Gurtner,et al.  Treating Chronic Wound Infections with Genetically Modified Free Flaps , 2009, Plastic and reconstructive surgery.

[31]  R. Herzog,et al.  Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. , 2009, Blood.

[32]  Geoffrey C. Gurtner,et al.  Using Genetically Modified Microvascular Free Flaps to Deliver Local Cancer Immunotherapy with Minimal Systemic Toxicity , 2008, Plastic and reconstructive surgery.

[33]  K. Ponder,et al.  Walk a mile in the moccasins of people with haemophilia , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[34]  Deirdre M. Jones,et al.  Plastic Surgical Delivery Systems for Targeted Gene Therapy , 2008, Annals of plastic surgery.

[35]  S. Darby,et al.  Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. , 2007, Blood.

[36]  D. DiMichele.  Inhibitor development in haemophilia B: an orphan disease in need of attention , 2007, British journal of haematology.

[37]  G. Gurtner,et al.  Biologic Brachytherapy: Ex Vivo Transduction of Microvascular Beds for Efficient, Targeted Gene Therapy , 2006, Plastic and reconstructive surgery.

[38]  R. Liesner,et al.  The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation , 2006, British journal of haematology.

[39]  J. Rasko,et al.  Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response , 2006, Nature Medicine.

[40]  C. Contag,et al.  Emission spectra of bioluminescent reporters and interaction with mammalian tissue determine the sensitivity of detection in vivo. , 2005, Journal of biomedical optics.

[41]  F. Larcher,et al.  A cutaneous gene therapy approach to treat infection through keratinocyte‐targeted overexpression of antimicrobial peptides , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  Deirdre M. Jones,et al.  Ex Vivo Transduction of Microvascular Free Flaps for Localized Peptide Delivery , 2004, Annals of plastic surgery.

[43]  I. Verma,et al.  Gene therapy with viral vectors. , 2003, Annual review of pharmacology and toxicology.

[44]  Alan McClelland,et al.  AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. , 2003, Blood.

[45]  E. Check.  Cancer fears cast doubts on future of gene therapy , 2003, Nature.

[46]  C. Slaughter,et al.  Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. , 2002, Blood.

[47]  D. Scherman,et al.  Minicircle: an improved DNA molecule for in vitro and in vivo gene transfer , 1999, Gene Therapy.

[48]  E. Tuddenham,et al.  Epidemiology of coagulation disorders. , 1992, Bailliere's clinical haematology.

[49]  G. Acsadi,et al.  Direct gene transfer into mouse muscle in vivo. , 1990, Science.

[50]  M. Siemionow,et al.  Ischemia/reperfusion injury: A review in relation to free tissue transfers , 2004, Microsurgery.

[51]  F W Pirruccello,et al.  Plastic and reconstructive surgery. , 1967, IMJ. Illinois medical journal.